Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 5, 2025
Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
• Quarterly record revenue in Q2 of $21M, +43% year-over-year growth; IFRS gross margin of 75.5% • Second quarter pulse recurring revenue of $9.2M, +53% year-over-year growth • First half revenue of $37.6M, +35% year-over-year growth; IFRS gross margin of …
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
GlobeNewswire
·
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork …
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
GlobeNewswire
·
August 5, 2025
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a …
Clene to Present at the Canaccord 45th Annual Growth Conference
GlobeNewswire
·
August 5, 2025
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
GlobeNewswire
·
August 5, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, …
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
GlobeNewswire
·
August 5, 2025
CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and …
Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025
GlobeNewswire
·
August 5, 2025
LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release second quarter 2025 financial results on Monday, August 11, 2025, after the market close. …
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
GlobeNewswire
·
August 5, 2025
HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (" …
Conduit to Change Name to CDT Equity Inc.
GlobeNewswire
·
August 5, 2025
Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United …
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
GlobeNewswire
·
August 5, 2025
Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs …
Bioma Probiotics Launches Science-Backed Gut Health Formula for Women’s Natural Weight Loss
GlobeNewswire
·
August 5, 2025
New York City, NY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Weight loss is more than calories in versus calories out—it’s a battle that often begins in the gut. Millions of people, particularly women, face a frustrating cycle of dieting, fatigue, and weight gain. …
Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
GlobeNewswire
·
August 5, 2025
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a …
Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow® System Under New CMS Code
GlobeNewswire
·
August 5, 2025
MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming fluid management, today announced that the first patients have been successfully treated with Aquadex® ultrafiltration …
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
GlobeNewswire
·
August 5, 2025
IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), …
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
GlobeNewswire
·
August 5, 2025
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139 (semaglutide …
CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
GlobeNewswire
·
August 5, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical Manufacturing Preparedness …
HOOPP launches 2030 Strategic Plan to build a stronger financial future for Ontario’s healthcare community
GlobeNewswire
·
August 5, 2025
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) is proud to announce the launch of its 2030 Strategic Plan, a forward-thinking roadmap designed to reinforce the Plan’s mission of delivering on our pension promise …
Mesa Labs Announces First Quarter Results
GlobeNewswire
·
August 5, 2025
LAKEWOOD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“ …
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire
·
August 5, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for …
Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers
GlobeNewswire
·
August 5, 2025
- Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand - Company positioned to lead in dense breast imaging, where rising incidence and new screening mandates are …